GROW
U.S. Global Investors, Inc.
There isn't enough reported data to score GROW yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
GROW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
GROW's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like GROW.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
GROW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4x | $0.52 | -79% |
| Fair | 13x | $1.68 | -33% |
| Current | 19x | $2.52 | — |
| Expensive | 35x | $4.53 | +80% |
Historical ranges are pointers, not guarantees.
GROW's PE is 19x, but its earnings don't support one, so it isn't a reliable read right now.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over GROW in the historical PE scenario, which offers more potential upside but is not a forecast.
GROW Forward outlook
There aren't enough analyst estimates for GROW to show an outlook.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
GROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.13 | +86% |
| Q2 2026 | $0.24 | +$0.27 |
| Q1 2026 | $0.25 | +$0.26 |
| Q4 2025 | $0.01 | -50% |
| Q3 2025 | $0.07 | -42% |
| Q2 2025 | -$0.03 | -133% |
| Q1 2025 | -$0.01 | -108% |
| Q4 2024 | $0.02 | -91% |
GROW's earnings per share have fallen from their peak: $0.13 over the past year, against $2.15 in late 2021.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over GROW on earnings, with more consistent year-over-year improvement.
GROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7M | +18% |
| Q2 2026 | $2.7M | +39% |
| Q1 2026 | $2.8M | +31% |
| Q4 2025 | $2.5M | +13% |
| Q3 2025 | $2.3M | +4.4% |
| Q2 2025 | $2M | -20% |
| Q1 2025 | $2.1M | -19% |
| Q4 2024 | $2.2M | -21% |
GROW's revenue is recovering but still below its 2021 peak: $3M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.1% | +25 points |
| Q2 2026 | -3.2% | +48 points |
| Q1 2026 | 3.2% | +46 points |
| Q4 2025 | -3.5% | +21 points |
| Q3 2025 | -23% | +3 points |
| Q2 2025 | -51% | -35 points |
| Q1 2025 | -42% | -24 points |
| Q4 2024 | -24% | -31 points |
GROW's operating margin was 2.1% last quarter, up 25 points from the same quarter a year ago.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over GROW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over GROW on profitability, with a higher operating margin.
GROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $483K | +$515K |
| Q2 2026 | $203K | +$218K |
| Q1 2026 | $275K | +$699K |
| Q3 2025 | -$32K | -300% |
| Q2 2025 | -$15K | -115% |
| Q1 2025 | -$424K | -$299K |
| Q4 2024 | -$406K | -$380K |
| Q3 2024 | $16K | -98% |
GROW has the stronger cash trend. Its trailing FCF is down 72% versus its history, compared with JPM at down 229%.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
GROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.8% | -360K shares |
| 1 year | -5% | -648K shares |
| 3 years | -15% | -2.1M shares |
| 5 years | -18% | -2.7M shares |
| Available history | -19% | -2.8M shares |
GROW has the edge over JPM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $320,000 |
| Q2 2026 | $364,000 |
| Q1 2026 | $552,000 |
| Q4 2025 | $666,000 |
| Q3 2025 | $390,000 |
| Q2 2025 | $395,000 |
| Q1 2025 | $453,000 |
| Q4 2024 | $591,000 |
GROW spent $2M buying back its own shares over the past year, up 4% from the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
GROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2,691.6x | Net Cash |
| Q1 2024 | -61.7x | Net Cash |
| Q4 2023 | -16.3x | Net Cash |
| Q3 2023 | -11.2x | Net Cash |
| Q2 2023 | -6.7x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
| Q4 2022 | -2.9x | Net Cash |
| Q3 2022 | -2.3x | Net Cash |
GROW has the edge over JPM on leverage, with a lower net debt burden relative to earnings.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
GROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 6.4 | Oversold |
GROW's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
GROW PE vs Financial Services Sector
| Metric | GROW | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 13x | 49% above |
| PE % | 60 | 63 | 3 pts below |
GROW is trading at 19x earnings, a 49% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over GROW on valuation relative to its sector.
GROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.72 | 7.4% below |
| 20 week MA | $2.92 | 14% below |
| 50 week MA | $2.84 | 11% below |
| 100 week MA | $2.62 | 3.8% below |
| 200 week MA | $2.68 | 6% below |
GROW is in a downtrend: it's below all five of its weekly moving averages, and 6% below its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over GROW on trend strength, trading above more of its moving averages.
GROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.33 | $4.62 | +247% |
| 2021 | $4.62 | $4.55 | -1.5% |
| 2022 | $4.55 | $2.65 | -42% |
| 2023 | $2.65 | $2.82 | +6.4% |
| 2024 | $2.82 | $2.45 | -13% |
| 2025 | $2.45 | $2.47 | +0.8% |
| 2026 YTD | $2.47 | $2.52 | +2% |
GROW's yearly returns have swung widely, from +247% in 2020 to −42% in 2022. It's up 2% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over GROW on returns for 2026, with the stronger performance.